Screening Guidelines: Ages to Initiate and Stop and Opportunistic Screening (2025)-S4-CBR02-2025

Video Transcription

Video Summary

The transcript reviews breast cancer screening start/stop ages and practices across the U.S., Europe, and Canada, emphasizing how differing guidelines affect outcomes and equity.

In the U.S., 2024 estimates cite ~310,000 invasive cases, 56,000 DCIS, and 42,250 deaths, with mortality down 44% since 1989 but declines slowing—especially in women <40 and >75. Major ethnic disparities persist: Black women have slightly lower incidence than White women but much higher mortality. Most U.S. societies now support starting screening at 40, often annually, with modeling (CISNET) suggesting annual DBT from 40 to at least 79 maximizes deaths averted and life-years gained, despite more non-lethal false positives. Speakers argue screening should continue beyond 74 as long as a woman is healthy, because incidence and deaths remain high after 75.

European perspectives highlight organized, population-based programs (often ages 50–70/75, usually biennial) with double reading; attendance is declining and some countries lack programs. EU guidance generally discourages screening <40 and >75, is cautious on AI and density-based MRI, though some societies recommend MRI for extremely dense breasts.

Canada has provincial organized programs, expanding access for ages 40–49 despite federal task force hesitation. Early Ontario data show strong uptake with similar recall rates but longer waits due to staffing shortages. Most provinces stop at 74; participation remains ~60%, and “opportunistic” screening gaps worsen inequities.

Keywords

breast cancer screening guidelines

screening start age 40

screening stop age 74 75

annual vs biennial mammography

digital breast tomosynthesis DBT

CISNET modeling outcomes

health equity racial disparities Black women mortality

organized population-based screening programs

Canada provincial screening programs access 40-49